Sub-group of colorectal cancers responds to anti-EGFR treatment


  • Dawn O'Shea
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Patients with colorectal cancer (CRC) with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment, according to a research led by Memorial Sloan Kettering Cancer Center in New York.

The multicentre pooled analysis included patients with non-V600 BRAF-mutated metastatic CRC (mCRC) identified between 2010 and 2017. Mutations were divided into functional classes: activating and RAS-independent (class 2) or kinase-impaired and RAS-dependent (class 3).

A total of 12 patients (30%) with class 2 mutations and 28 with class 3 mutations (70%) received anti-EGFR antibody treatment. No significant differences in clinical characteristics were observed by mutation class.

However, while only one of 12 patients with class 2 BRAF mCRC responded to anti-EGFR therapy, 14 of 28 patients with class 3 BRAF responded (response rate, 8% and 50%, respectively; P=.02). In the first- or second-line setting, one of six (17%) patients with class 2 and seven of nine (78%) patients with class 3 BRAF mutations responded (P=.04). In third- or later-line treatment, none of six patients with class 2 and seven of 19 (37%) patients with class 3 BRAF mutations responded (P=.14).

The authors concluded that patients with CRC with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment.